Compare AbbVie Inc (ABBV) vs Domino's Pizza, Inc. (DPZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Domino's Pizza, Inc. — how do they compare? AbbVie Inc trades at $253.56 (market cap $449.91B), while Domino's Pizza, Inc. trades at $302.65 (market cap $10.42B). The key difference: AbbVie Inc is far larger — about 43.2× Domino's Pizza, Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | DPZ | |
|---|---|---|
Market Cap | $449.91B | $10.42B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $485.53 |
52-Week Low | $184.85 | $282.89 |
Enterprise Value | $513.38B | $15.32B |
Dividend Yield | 2.72% | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Domino's Pizza (DPZ) trades at $313.14, up 0.47% on the day, but remains near its 52-week low amid a bearish technical trend. The company reported mixed Q1 2026 earnings with an EPS miss of $4.13 vs. $4.27 expected, though revenue growth has been steady, reaching $4.94B in 2025. Analyst consensus is bullish with a $386.07 price target, but recent CEO transition and slowing same-store sales present near-term headwinds. Cash flow from operations remains strong at $792M in 2025, supporting dividends and buybacks.
DPZ offers value with a P/E of 17.6x and solid profitability (net margin 11.9%), but high debt levels and competitive pressures pose risks. The stock's 25% YTD decline creates a potential entry point for long-term investors, though execution under new leadership and consumer spending trends will be critical for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →
